Analysis of contracts, countries sign with vaccinators to promote candidates, shows that the agreements are still flowing, changing after a few days, with some companies winning and some losing orders as most candidates are still in phase.
Among vaccine manufacturers, orders with Oxford-Astrazeneca have dropped more than 30 million doses to reach 2.47 billion, compared with 2.5 billion as of Nov. 30, while the Pfizer-BioNTech vaccine, the only one administered to humans to date. , saw additional orders for 73.2 million to touch 719 million as of December 11th. Modern has seen new deals for 29 million doses.
However, both Oxford and India are at the top of the table. While Oxford still has orders for most doses, India, as an individual country, has most contracts with the EU region alone, with 85 million more doses, previously.
According to Duke data, the Russian Gamaleya Research Institute, the creator of Sputnik-V, has lost orders of 153 million doses – including 100 million doses from India. In India, Dr. Reddy’s laboratory, based in Hyderabad, is conducting local tests of Sputnik-V.
However, the Russian Direct Investment Fund (RDIF), which has partnered with Dr Reddy’s Laboratory for Sputnik-V in India, told TOI on Monday that the order for 100 million doses remains “confirmed” and is not off the table.
On December 1, Dr. Reddy’s lab said it had received authorization for phase 2/3 clinical trials, and experts indicated that acquisition of this candidate could take place in the future.
TOI tracked the Launch & Scale Speedometer, which to date has the most comprehensive data on global deals with regular updates. Data showed that compared to November 30, the overall doses of vaccines for which contracts existed jumped by 171 million by December 4, before falling to the current level.
On 4 December Oxford-Astrazeneca still had contracts for their 2.5 billion doses, while India would still secure 1.6 billion. Pfizer saw a slight jump from 646 million on November 30 to 656 million doses before crossing the 700 million mark according to the December 11 analysis. And Gamaleya’s order has actually risen slightly from the 300 million it had by the end of last month.
Indian Health Secretary Rajesh Bhushan indicated in a press conference last week that the country plans to inoculate about 30 crore in the first three rounds – 3 crore doctors and first workers and about 27 crore with comorbidities over 50 years old.